BGNE - BeiGene, Ltd.
Pre-Market:
| Previous Close | 228.27 |
| Open | 225.68 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 213.82 - 226.10 |
| 52 Week Range | 124.46 - 280.62 |
| Volume | |
| Avg. Volume | 195,209 |
| Market Cap | 23.988B |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -18.51 |
| Earnings Date | Aug 08, 2018 - Aug 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 316.74 |
Business WireBRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., May 30, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor (BTKi), has been approved by Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
CNW GroupHealth Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults
BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor, has been granted a Notice of Compliance from Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL).
Business WireBeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., May 25, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data showcasing the range of BeiGene’s research expertise and the productivity of one of the industry’s largest research and development teams at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These results include data for BeiGene’s cornerstone therapies, BRUKINSA® (zanubrutinib)
Simply Wall St.Institutional investors are BeiGene, Ltd.'s (NASDAQ:BGNE) biggest bettors and were rewarded after last week's US$813m market cap gain
Key Insights Significantly high institutional ownership implies BeiGene's stock price is sensitive to their trading...
Business WireBeiGene to Present at Upcoming Investor Conferences
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., May 24, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences:
Business WireThe Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
SEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., May 17, 2023--The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic le
Business WireBeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., May 06, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA) approved four applications for BRUKINSA (zanubrutinib), the company’s Bruton’s tyrosine kinase inhibitor (BTKi), including two Supplemental New Drug Applications for treatment-naïve adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and Waldenström'
- Simply Wall St.
BeiGene First Quarter 2023 Earnings: EPS Beats Expectations
BeiGene ( NASDAQ:BGNE ) First Quarter 2023 Results Key Financial Results Revenue: US$447.8m (up 46% from 1Q 2022). Net...
Business WireBeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., May 04, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the first quarter 2023, recent business highlights, and upcoming milestones.
Business WireBeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 26, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will present data from its broad solid tumor and hematology portfolio at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting in Chicago, June 2-6, 2023.
Motley Fool3 Top Biotech Stocks Defying the Bear Market
The bear market for biotech stocks has recently shown signs of slackening, but there are biotech stocks whose shares are already up by 50% or more to start this year. TG Therapeutics (NASDAQ: TGTX), Viking Therapeutics (NASDAQ: VKTX) and BeiGene (NASDAQ: BGNE) have attracted investors' interest because they all have new therapies with wide applications that have shown great promise. TG Therapeutics' launch of Briumvi, a therapy for relapsing multiple sclerosis, has been a quick success, even with competition from two other anti-CD20 monoclonal antibodies already on the market.
Business WireBeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 25, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced several new Environmental, Social, and Governance (ESG) goals today, including targets related to carbon emissions and workforce diversity. These goals are outlined in the Company’s newly released "Change Is the Cure: 2022 Environmental, Social and Governance Report." The report highlights BeiGene’s ESG strategy, the progress the Company has
Business WireBeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 20, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its primary endpoint of overall survival, with tislelizumab in combination with chemotherapy demonstrating superior overall survival (OS) compared with chemotherapy in patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, regardless of PD-L1 sta
Business WireBeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & STAMFORD, Conn., April 17, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in combination with SpringWorks’ MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors with RAS mutations, RAF mutations and other MAPK pathway aberra
GlobeNewswireSpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in combination with SpringWorks’ MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors with RAS mutations, RAF mutations and
GlobeNewswireMapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass. and SAN MATEO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- MapKure, LLC, SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective RAF dimer inhibitor, in adult patients with advanced or refractory solid tumors harboring MAPK pathway aberrations. Th
Business WireMapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn., April 17, 2023--MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective RAF dimer inhibitor, in adult patients with advanced or refractory solid tumors harboring MAPK pathway aberrations. The data are being presented
- Simply Wall St.
BeiGene, Ltd.'s (NASDAQ:BGNE) Business Is Yet to Catch Up With Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 19.5x BeiGene, Ltd. ( NASDAQ:BGNE ) is a stock to avoid...
Business WireBeiGene Expands Presence in Latin America With Opening of Brazil Office
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 13, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the first major step in the company’s expansion in Latin America (LATAM) with the formal opening of its office in São Paulo, Brazil.
ZacksBeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Motley FoolWhy BeiGene Stock Jumped Thursday
Shares of BeiGene (NASDAQ: BGNE) rose 14.3% by late Thursday afternoon and closed the day 12.48% higher. The Chinese biotech company recently signed a collaboration deal with Israel biotech company Enlivex Therapeutics to evaluate the safety and efficacy of cancer therapy Allocetra as a combination therapy with tislelizumab, which BeiGene will supply, to treat advanced-stage solid tumors. BeiGene's shares are up more than 8% so far this year.
Business WireBeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 30, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately.
- Simply Wall St.
Investing in BeiGene (NASDAQ:BGNE) three years ago would have delivered you a 75% gain
One simple way to benefit from the stock market is to buy an index fund. But many of us dare to dream of bigger...
Business WireBeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 21, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is entering a new phase as it continues to build its U.S. presence. The company announced today that the last piece of structural steel will be laid at its Hopewell, NJ campus today. This new facility will provide state-of-the-art commercial-stage U.S. biologic pharmaceutical manufacturing, late-stage research and clinical development capabilities tha
ZacksPrelude (PRLD) Collaborates With BeiGene for Oncology Candidate
Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.